查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1935552

全球抗病毒藥物市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Antiviral Drugs Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計抗病毒藥物市場規模將從 2025 年的 741.2 億美元成長到 2034 年的 1,288.8 億美元，2026 年至 2034 年的複合年成長率為 6.34%。

受病毒感染疾病不斷增加以及對有效治療方案持續需求的推動，全球抗病毒藥物市場預計將迎來顯著成長。隨著流感、愛滋病和肝炎等新型病毒病原體的出現，全球對抗病毒藥物的需求比以往任何時候都更加迫切。抗藥性病毒株的出現進一步加劇了治療選擇的複雜性，促使製藥公司加快對新型抗病毒藥物研發的投資。這種對創新的重視有望透過推出應對現有和新出現的病毒威脅的新療法來推動市場擴張。

此外，人們對醫療保健和疫苗接種重要性的認知不斷提高，預計將推動抗病毒藥物市場的發展。隨著公共衛生政策強調接種疫苗預防病毒感染疾病的必要性，對用於輔助這些工作的抗病毒藥物的需求將會增加。將抗病毒療法與疫苗接種計劃相結合，將有助於全面改善疾病管理和控制，尤其是在高風險族群中。此外，諸如新冠肺炎疫情等持續的全球衛生危機凸顯了抗病毒研究的重要性，促使抗病毒藥物的研發進程加快，並增加了相關研究經費。

此外，生物技術和個人化醫療的進步有望塑造抗病毒藥物市場的未來。針對特定病毒作用機制和患者特徵的標靶治療正在研發中取得進展，有望提供更有效、更個人化的治療方案。此外，聯合治療（將多種抗病毒藥物合併使用以提高療效並降低抗藥性）的興起正成為控制病毒感染疾病的關鍵策略。製藥公司、研究機構和醫療服務提供者之間的合作對於推動這些創新至關重要，並確保抗病毒藥物市場能夠持續適應不斷變化的病毒性疾病情況。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 繪製滲透率和成長前景圖
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制
    • 市場機遇
    • 市場問題
  • 波特五力分析
  • PESTLE分析

4. 全球抗病毒藥物市場（依藥物類別分類）

  • 市場分析、洞察與預測
  • 核苷類似物
  • 蛋白酶抑制劑
  • 聚合酵素抑制劑
  • 其他

5. 全球抗病毒藥物市場（按應用分類）

  • 市場分析、洞察與預測
  • HIV
  • 肝炎
  • 流感
  • 皰疹
  • 其他

6. 全球抗病毒藥物市場按分銷管道分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

7. 全球抗病毒藥物市場（按地區分類）

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商格局（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Gilead Sciences Inc
    • GlaxoSmithKline Plc
    • Bristol-Myers Squibb Company
    • Merck & Co. Inc
    • Johnson & Johnson
    • Roche Holding AG
    • Pfizer Inc
    • AstraZeneca Plc
    • Novartis AG
    • Sanofi SA
    • Boehringer Ingelheim International GmbH
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd
    • Sun Pharmaceutical Industries Ltd
    • Dr. Reddy'S Laboratories Ltd
簡介目錄
Product Code: VMR11211443

The Antiviral Drugs Market size is expected to reach USD 128.88 Billion in 2034 from USD 74.12 Billion (2025) growing at a CAGR of 6.34% during 2026-2034.

The global antiviral drugs market is set to witness substantial growth, driven by the increasing prevalence of viral infections and the ongoing need for effective therapeutic solutions. As the world faces the challenges posed by emerging viral pathogens, including influenza, HIV, and hepatitis, the demand for antiviral medications is more critical than ever. The rise of drug-resistant viral strains further complicates treatment options, prompting pharmaceutical companies to invest in research and development of novel antiviral agents. This focus on innovation is expected to propel market expansion, as new therapies are introduced to combat existing and emerging viral threats.

Moreover, the growing awareness of preventive healthcare and the importance of vaccination are set to bolster the antiviral drugs market. As public health initiatives emphasize the need for vaccination against viral infections, the demand for antiviral drugs that complement these efforts will increase. The integration of antiviral therapies with vaccination programs can enhance overall disease management and control, particularly in high-risk populations. Additionally, the ongoing global health crises, such as the COVID-19 pandemic, have underscored the importance of antiviral research, leading to accelerated development timelines and increased funding for antiviral drug discovery.

In addition, advancements in biotechnology and personalized medicine are expected to shape the future of the antiviral drugs market. The development of targeted therapies that address specific viral mechanisms and patient profiles is gaining traction, offering the potential for more effective and tailored treatment options. Furthermore, the rise of combination therapies that utilize multiple antiviral agents to enhance efficacy and reduce resistance is becoming a key strategy in managing viral infections. Collaborative efforts between pharmaceutical companies, research institutions, and healthcare providers will be essential in driving these innovations, ensuring that the antiviral drugs market remains responsive to the evolving landscape of viral diseases.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

  • Nucleoside Analogs
  • Protease Inhibitors
  • Polymerase Inhibitors
  • Others

By Application

  • HIV
  • Hepatitis
  • Influenza
  • Herpes
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • Gilead Sciences Inc, GlaxoSmithKline plc, BristolMyers Squibb Company, Merck Co Inc, Johnson Johnson, Roche Holding AG, Pfizer Inc, AstraZeneca plc, Novartis AG, Sanofi SA, Boehringer Ingelheim International GmbH, Mylan NV, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Dr Reddys Laboratories Ltd

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTIVIRAL DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Class
  • 4.2. Nucleoside Analogs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Protease Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Polymerase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTIVIRAL DRUGS MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. HIV Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Hepatitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Herpes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Distribution Channel
  • 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTIVIRAL DRUGS MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Drug Class
    • 7.2.2 By Application
    • 7.2.3 By Distribution Channel
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Drug Class
    • 7.3.2 By Application
    • 7.3.3 By Distribution Channel
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Drug Class
    • 7.4.2 By Application
    • 7.4.3 By Distribution Channel
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Drug Class
    • 7.5.2 By Application
    • 7.5.3 By Distribution Channel
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Drug Class
    • 7.6.2 By Application
    • 7.6.3 By Distribution Channel
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ANTIVIRAL DRUGS INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Gilead Sciences Inc
    • 9.2.2 GlaxoSmithKline Plc
    • 9.2.3 Bristol-Myers Squibb Company
    • 9.2.4 Merck & Co. Inc
    • 9.2.5 Johnson & Johnson
    • 9.2.6 Roche Holding AG
    • 9.2.7 Pfizer Inc
    • 9.2.8 AstraZeneca Plc
    • 9.2.9 Novartis AG
    • 9.2.10 Sanofi S.A
    • 9.2.11 Boehringer Ingelheim International GmbH
    • 9.2.12 Mylan N.V
    • 9.2.13 Teva Pharmaceutical Industries Ltd
    • 9.2.14 Sun Pharmaceutical Industries Ltd
    • 9.2.15 Dr. Reddy'S Laboratories Ltd